Proviral Landscape in Neonates with in utero HIV-1 Receiving Very Early ART in IMPAACT P1115

Soumia K. Bekka[1], Priya Khetan[1], Yufeng Liu[1], Adit Dhummakupt[1], Bryan S. Nelson[2], Camlin Tierney[2], Ellen Chadwick[3,4], Jennifer Jao[3,4], Yvonne Bryson[5], Anne Coletti[6], Nicol Nicodimus[7], Lynda Stranix-Chibanda[8], Guinevere Q. Lee[9], Stuart Ray[1], Deborah Persaud[1]

[1] Johns Hopkins University School of Medicine, Baltimore, MD, USA, [2]Harvard T.H. Chan School of Public Health, Boston, MA, USA, [3]Northwestern University Feinberg School of Medicine, Chicago, IL, USA, [4]Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA, [5]University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA, [6]FHI 360, Durham, NC, USA, [7]University of Zimbabwe, Clinical Trials Research Centre, Harare, Zimbabwe, [8]University of Zimbabwe, Child and Adolescent Health Unit, Faculty of Medicine and Health Science, Clinical Trials Research Centre, Harare, Zimbabwe, [9]Infectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York, NY, USA

0954

BACKGROUND

Data on the proviral landscape in neonates with in utero HIV-1 infection are limited. We performed near full-length single HIV-1 genome sequencing (nFLSGS) to analyze the proviral landscape and estimate intact proviral loads among 25 neonates with in utero HIV-1 who initiated very early ART in IMPAACT P1115 (NCT02140255)[1,2,3].

METHODS

Study Population

440 neonates in Cohort 1 of IMPAACT P1115 pre-emptively initiated ART within 48 hours of birth.

In utero HIV-1 infection was confirmed in 36 neonates, with 34 continuing on-study.

Eligibility Criteria

nFLSGS was performed on neonates with:

- HIV-1 DNA loads >20 copies/10^6 (c/10^6) peripheral blood mononuclear cells (PBMCs)
- Sufficient remnant genomic DNA

Droplet Digital PCR (ddPCR)

Total HIV-1 DNA from PBMCs measured by ddPCR was used to standardize the HIV-1 DNA input for nFLSGS.

Near Full-Length Single Genome Sequencing

A nFL outer 9kb followed by a nFL inner 9kb were performed limiting dilution to ensure single genome amplification.

Sequencing using Illumina MiSeq was performed at the Massachusetts General Hospital CCIB DNA Core.

Viral Genome Bioinformatics Analysis

Genomes were classified using HIVSeqinR[3] (v2.7.1) as **intact**, **defective**, or **hypermutated**

Manual evaluation was required for subtypes A1 and AE.

Quantification of Intact Proviral Load

Intact HIV-1 proviral load was calculated as $\left[\frac{I}{C}\right] \times e$.

I = number of intact HIV-1 proviral genomes obtained via nFLSGS
C = total cellular equivalents analyzed in standardized input of HIV-1 DNA
e = efficiency correction constant

When intact proviral genomes were not detected, data were calculated as 0.5 intact proviral genomes per cell equivalents tested without target identification.

Intact HIV-1 DNA load was normalized to c/10^6 PBMCs.

Phylogenetic Analyses

Sequences were aligned with MAFFT (v7) and the maximum likelihood tree was built using IQ-TREE (v2).

Sequences for HIV-1 subtypes B (HXB2), A1, AE and C were included for reference.

Statistical Methods

A two-sided signed rank test was performed for analysis of intact HIV-1 DNA load at birth and 2 weeks post-birth.

The proviral landscape at birth in neonates with in utero HIV-1 includes a **complex mix** of **intact**, **defective**, and **hypermutated** **genomes**, indicating **ongoing HIV-1 replication in fetal cells.**

RESULTS

- 25 of 34 neonates met criteria for analysis; n=21 at birth, n=18 at 2 weeks post-birth, n=14 at both timepoints.
- Median proviral genomes (Q1, Q3) [min, max] is 5 (3, 7) [1, 11] at birth and 5.5 (2.3. 10) [1, 20] 2 weeks post-birth.



Figure 1. Proviral landscape analyses at birth (left; 114 genomes from *n*=21) and 2 weeks post-birth (right; 113 genomes from *n*=18), sorted by percent intact proviral genomes at birth. White boxes indicate insufficient volume for nFLSGS (*n*=4 at birth; *n*=3 at 2 weeks post-birth). Red hatched boxes indicate <20 cpm HIV-1 DNA at a given timepoint (*n*=1 at 2 weeks post-birth).



Figure 2. Distribution of intact and defective proviral genomes identified at birth (114 genomes) and 2 weeks post-birth (113 genomes).



Figure 3. Maximum likelihood phylogenetic tree of 91 intact HIV-1 proviral genomes at birth (58 genomes) and 2 weeks post-birth (33 genomes), showing participant-specific clustering (*n*=21). Intacts were not detected in neonates R, S, U, and Y.



Figure 4. Intact HIV-1 DNA load from birth to 2 weeks post-birth. Median intact proviral load (Q1, Q3) [min, max] is 141 (63, 352) [5, 880] at birth and 76 (27, 190) [2, 681] 2 weeks post-birth. Two-sided signed rank test performed at a 0.05 significance level. Open circles denote participants without detected intact proviral genomes.

Limitations

Only those with the minimum required proviral load for nFLSGS (>20 HIV-1 DNA c/10^6 PBMC) and sufficient remnant DNA could be studied.

Inherent inefficiency (27-30%) of 9kb nFLSGS PCR may underrepresent intact proviral genomes.

Current analyses are unable to discriminate between integrated vs unintegrated proviral genomes.

CONCLUSIONS

Intact, defective and hypermutated proviral genomes were identified at birth in neonates with in utero HIV-1, indicating ongoing HIV-1 replication in utero.

Intact proviral genomes comprise a substantial proportion of the proviral pool and share >99% identity through 2 weeks of life, supporting low diversity infection.

In the first 2 weeks of life, intact proviral loads decrease with very early ART, suggesting early clearance of infected cells harboring intact HIV-1 proviral genomes.

REFERENCES

1. Ruel TD, Capparelli EV, Tierney C, et al. **Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.** *Lancet HIV*. 2021;8(3):e149-e157.
2. Nelson BS, Tierney C, Persaud D, et al.**. Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life.** *Clin Infect Dis*. 2023 Feb 8;76(3):e744-e747.
3. Persaud D, Bryson Y, Nelson BS, et al. **HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.** *Lancet HIV*. 2024;11(1):e20-e30.
4. Lee GQ, Lichterfeld M. **Near-Full-Length Single-Genome HIV-1 DNA Sequencing**. *Methods Mol Biol*. 2022;2407:357-364.

ACKNOWLEDGEMENTS

We thank the study participants, clinical sites, and the PAVE CAB!
Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632-15 (IMPAACT LOC), UM1AI068616-15 (IMPAACT SDMC) and UM1AI106716-09 (IMPAACT LC), and by NICHD contract number HHSN275201800001I. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This research was also supported in part by the National Institutes of Health (R01AI150412 to DP), IMPAACT subspecialty laboratory (5UM1AI106716), HPTN Laboratory Center (UM1-AI068613), the PAVE Martin Delaney Collaboratory (UM1AI164566), and the Johns Hopkins Center for AIDS Research (P30 AI094189). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID.

AUTHOR CONTACT INFO

Soumia Bekka, sbekka1@jhmi.edu
Deborah Persaud, dpers@jhmi.edu